SI3295951T1 - Anti-PVRIG protitelesa in metode uporabe - Google Patents

Anti-PVRIG protitelesa in metode uporabe

Info

Publication number
SI3295951T1
SI3295951T1 SI201630837T SI201630837T SI3295951T1 SI 3295951 T1 SI3295951 T1 SI 3295951T1 SI 201630837 T SI201630837 T SI 201630837T SI 201630837 T SI201630837 T SI 201630837T SI 3295951 T1 SI3295951 T1 SI 3295951T1
Authority
SI
Slovenia
Prior art keywords
methods
pvrig antibodies
pvrig
antibodies
Prior art date
Application number
SI201630837T
Other languages
English (en)
Slovenian (sl)
Inventor
Mark White
Sandeep Kumar
Christopher Chan
Spencer Liang
Lance Stapleton
Andrew W. Drake
Yosi Gozlan
Ilan Vaknin
Shirley Sameah-Greenwald
Liat Dassa
Zohar Tiran
Gad S. Cojocaru
Leonard Presta
Richard Theolis
Original Assignee
Compugen Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55453315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3295951(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Compugen Ltd. filed Critical Compugen Ltd.
Publication of SI3295951T1 publication Critical patent/SI3295951T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
SI201630837T 2015-02-19 2016-02-19 Anti-PVRIG protitelesa in metode uporabe SI3295951T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562118208P 2015-02-19 2015-02-19
US201562141120P 2015-03-31 2015-03-31
US201562235823P 2015-10-01 2015-10-01
EP17192325.3A EP3295951B1 (en) 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use

Publications (1)

Publication Number Publication Date
SI3295951T1 true SI3295951T1 (sl) 2020-10-30

Family

ID=55453315

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201630837T SI3295951T1 (sl) 2015-02-19 2016-02-19 Anti-PVRIG protitelesa in metode uporabe
SI201630706T SI3258951T1 (sl) 2015-02-19 2016-02-19 Anti-pvrig protitelesa in metode uporabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201630706T SI3258951T1 (sl) 2015-02-19 2016-02-19 Anti-pvrig protitelesa in metode uporabe

Country Status (21)

Country Link
US (8) US10227408B2 (OSRAM)
EP (4) EP4129320A1 (OSRAM)
JP (2) JP7115856B2 (OSRAM)
KR (2) KR102669294B1 (OSRAM)
CN (2) CN115350275A (OSRAM)
AU (3) AU2016219835B2 (OSRAM)
CY (2) CY1122970T1 (OSRAM)
DK (3) DK3258951T3 (OSRAM)
ES (3) ES2806800T3 (OSRAM)
HR (3) HRP20221284T1 (OSRAM)
HU (3) HUE049032T2 (OSRAM)
IL (2) IL254039B2 (OSRAM)
LT (3) LT3258951T (OSRAM)
MX (2) MX374853B (OSRAM)
PL (3) PL3653221T3 (OSRAM)
PT (3) PT3653221T (OSRAM)
RU (1) RU2732042C2 (OSRAM)
SG (1) SG11201706583PA (OSRAM)
SI (2) SI3295951T1 (OSRAM)
WO (1) WO2016134333A1 (OSRAM)
ZA (1) ZA201706323B (OSRAM)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3243494B2 (ja) 1999-05-18 2002-01-07 独立行政法人産業技術総合研究所 チオフェン水素化脱硫用触媒及びその製造方法
US20130058957A1 (en) * 2010-02-23 2013-03-07 The University Of Tokyo Dendritic cell immunoreceptor agonist
MX386422B (es) 2013-12-20 2025-03-18 Fred Hutchinson Cancer Center Moléculas efectoras químericas etiquetadas y receptores de las mismas.
EP3259597B1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
MX374853B (es) 2015-02-19 2025-03-06 Compugen Ltd Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso.
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
KR20190080992A (ko) 2015-05-21 2019-07-08 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
WO2016196389A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
US10590198B2 (en) * 2015-08-28 2020-03-17 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
WO2017041004A1 (en) * 2015-09-02 2017-03-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG11201901077RA (en) 2016-08-17 2019-03-28 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EP3516044B1 (en) 2016-09-23 2025-04-16 Fred Hutchinson Cancer Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
MX2019010972A (es) 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
WO2018218072A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
BR112019025035A2 (pt) * 2017-06-01 2020-06-30 Compugen Ltd. método para tratar câncer
KR102869563B1 (ko) 2017-07-17 2025-10-10 얀센 바이오테크 인코포레이티드 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
EP3665191A4 (en) 2017-08-11 2021-05-05 Fred Hutchinson Cancer Research Center SPECIFIC BRAF TCRs AND RELATED USES
CA3071661A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center Strep-tag specific chimeric receptors and uses thereof
JP7319250B2 (ja) 2017-09-06 2023-08-01 フレッド ハッチンソン キャンサー センター Ｓｔｒｅｐ－タグ特異的結合タンパク質およびその使用
EP3678690A1 (en) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Methods for improving adoptive cell therapy
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
PL3694529T3 (pl) 2017-10-13 2024-12-16 Harpoon Therapeutics, Inc. Trójswoiste białka i sposoby zastosowania
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
SG11202008733YA (en) 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
KR102892725B1 (ko) 2018-05-09 2025-12-01 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 넥틴4에 특이적인 항체
CN112533948B (zh) 2018-05-31 2025-01-14 台湾醣联生技医药股份有限公司 与双触角Lewis B以及Lewis Y抗原结合的治疗性抗体
MX2020012797A (es) * 2018-06-01 2021-03-25 Compugen Ltd Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CN119841953A (zh) 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
MX2021000745A (es) 2018-07-20 2021-03-26 Surface Oncology Inc Composiciones anti-cd112r y metodos.
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
CA3109496A1 (en) 2018-08-22 2020-02-27 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
CA3111854A1 (en) * 2018-09-14 2020-03-19 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US20240165232A1 (en) 2018-09-24 2024-05-23 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
MX2021005308A (es) 2018-11-09 2021-09-08 Fred Hutchinson Cancer Center Star Receptores de celulas t especificos para mesotelina y su uso en inmunoterapia.
EP4292659A3 (en) 2018-12-19 2024-03-20 Humabs Biomed SA Antibodies that neutralize hepatitis b virus and uses thereof
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
WO2020163564A2 (en) * 2019-02-06 2020-08-13 Pionyr Immunotherapeutics, Inc. Anti-trem1 antibodies and related methods
WO2020172332A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
WO2021021837A2 (en) 2019-07-29 2021-02-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN114555790B (zh) 2019-08-20 2025-02-25 弗雷德哈钦森癌症中心 Wt-1特异性t细胞免疫疗法
US20220380441A1 (en) 2019-08-29 2022-12-01 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CA3160162A1 (en) * 2019-11-04 2021-05-14 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2021097294A1 (en) * 2019-11-15 2021-05-20 Surface Oncology, Inc. Compositions and methods for immunotherapy
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
WO2021180205A1 (zh) 2020-03-13 2021-09-16 江苏恒瑞医药股份有限公司 Pvrig结合蛋白及其医药用途
IL299201A (en) 2020-06-24 2023-02-01 Vir Biotechnology Inc Transgenic hepatitis B virus neutralizing antibodies and their uses
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US20250018036A1 (en) 2020-09-24 2025-01-16 Fred Hutchinson Cancer Center Immunotherapy targeting sox2 antigens
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
US20230288404A1 (en) * 2020-09-25 2023-09-14 Suzhou Ersheng Biopharmaceutical Co., Ltd. Detection method for tumor-specific t cells
WO2022076353A1 (en) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions and methods for treating mage-a1-expressing disease
WO2022090801A2 (en) * 2020-10-26 2022-05-05 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN112433055A (zh) * 2020-11-04 2021-03-02 上海药明生物技术有限公司 一种基于报告基因方法检测pvrig抗体的生物学活性的方法
EP4259651A2 (en) 2020-12-14 2023-10-18 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
US20240082397A1 (en) 2021-01-28 2024-03-14 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
US20240076373A1 (en) 2021-01-28 2024-03-07 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
CN114907479B (zh) * 2021-02-09 2024-12-31 上海君实生物医药科技股份有限公司 抗cd112r抗体及其用途
KR20230159823A (ko) 2021-02-11 2023-11-22 넥틴 테라퓨틱스 리미티드 Cd112r에 대한 항체 및 이의 용도
CN115925917A (zh) * 2021-03-08 2023-04-07 合肥天港免疫药物有限公司 抗pvrig蛋白抗体或抗体片段及其用途
JP2024511831A (ja) 2021-03-31 2024-03-15 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 抗原結合タンパク質およびそれらの組み合わせ
CN115010800B (zh) * 2021-06-10 2024-08-06 百奥赛图(北京)医药科技股份有限公司 Pvrig基因人源化非人动物的构建方法及应用
EP4363450A1 (en) * 2021-07-01 2024-05-08 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
US20250250319A1 (en) 2021-07-15 2025-08-07 Fred Hutchinson Cancer Center Chimeric transmembrane polypeptides comprising a tgf beta receptor extracellular domain, a transmembrane domain and an interleukin receptor 2 intracellular signalling domain and its use in therapy
JP7727086B2 (ja) 2021-07-30 2025-08-20 山▲東▼先声生物制▲薬▼有限公司 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
WO2023040940A1 (zh) * 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
JP2024535768A (ja) 2021-09-15 2024-10-02 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｐｖｒｉｇ／ｔｉｇｉｔ二重特異性抗体を含む医薬組成物
KR20240055080A (ko) 2021-09-15 2024-04-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CN115819582A (zh) * 2021-12-24 2023-03-21 合肥天港免疫药物有限公司 Pvrig的抗体或其抗原结合片段及其应用
CN114644711B (zh) * 2022-03-07 2025-03-04 南京诺艾新生物技术有限公司 重组抗人pvrig抗体及应用
MX2024011278A (es) 2022-03-15 2024-09-25 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
EP4245374A3 (en) * 2022-03-18 2024-07-10 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN116925222A (zh) 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pvrig抗体、其药物组合物及用途
CN116925233A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2023242247A1 (en) * 2022-06-14 2023-12-21 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
AR130172A1 (es) * 2022-08-10 2024-11-13 Beigene Ltd Anticuerpos anti-pvrig y métodos de uso
WO2024046245A1 (zh) * 2022-08-31 2024-03-07 石药集团巨石生物制药有限公司 抗pvrig抗体及其应用
CN120187755A (zh) * 2022-11-10 2025-06-20 华辉安健（北京）生物科技有限公司 抗cd112r抗体及其用途
CN120418289A (zh) 2022-12-14 2025-08-01 安斯泰来制药欧洲有限公司 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
EP4644419A1 (en) 2022-12-30 2025-11-05 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Antibody targeting cd112r or antigen-binding fragment thereof and use thereof
WO2024182443A2 (en) 2023-02-27 2024-09-06 Compugen Ltd. Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
WO2024251160A1 (en) * 2023-06-06 2024-12-12 Wuxi Biologics (Shanghai) Co., Ltd. Anti-pvrig antibodies and uses thereof
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
CN119841952B (zh) * 2023-12-22 2025-11-04 华润生物医药有限公司 抗pvrig抗体及其用途
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
CN119193693B (zh) * 2024-08-06 2025-06-13 湖南农业大学 重组质粒及其制备方法、蛋白组合物、用途、疫苗、组合疫苗
CN120058919B (zh) * 2025-04-29 2025-07-18 浙江大学杭州国际科创中心 抗裂谷热病毒Gn蛋白的单抗及在病毒检测中的应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2002537805A (ja) 1999-03-05 2002-11-12 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト分泌タンパク質
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
JP2004536585A (ja) 2001-05-09 2004-12-09 エール・ユニバーシティ トル／インターロイキン−１受容体アダプタータンパク質（ｔｉｒａｐ）
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
EP1498485A4 (en) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk MODIFIED GENOME CELLS
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
JP2006516089A (ja) 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2004058805A2 (en) * 2002-12-26 2004-07-15 Asahi Kasei Pharma Corporation T cell activating gene
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1709080B1 (en) 2004-01-09 2011-03-09 Pfizer Inc. ANTIBODIES TO MAdCAM
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7622265B2 (en) 2005-02-22 2009-11-24 Genentech, Inc. Methods and compositions for modulating prostasin
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
US20070243584A1 (en) 2006-04-13 2007-10-18 West James W Tetramerizing polypeptides and methods of use
CA2648915A1 (en) 2006-04-13 2007-11-01 Zymogenetics, Inc. Tetramerizing polypeptides and methods of use
US20090318376A1 (en) 2006-06-15 2009-12-24 Korea Research Institute Of Bioscience And Biotechnology High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
BRPI0717024A2 (pt) * 2006-10-06 2014-03-11 Takeda Pharmaceutical Anticorpo, célula de hibridoma, agente de diagnótico, medicamento, métodos para prevenir/tratar câncer, para induzir apoptose células cancerosas , para inibir crescimento de células cancerosas e para destruir células cancerosas, uso de um anicorpo monoclonal e agente para prevenir ou tratar câncer de mama.
AU2008282863A1 (en) * 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
EP3605088A1 (en) 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2010109924A1 (ja) 2009-03-25 2010-09-30 国立大学法人東北大学 Ｌｈ型二重特異性抗体
US20110217297A1 (en) 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
WO2012129488A2 (en) 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
WO2012156515A1 (en) 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
CA2840946A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
SG11201401791WA (en) 2011-10-24 2014-08-28 Abbvie Inc Immunobinders directed against sclerostin
EP2858673A4 (en) 2012-06-06 2016-06-22 Oncomed Pharm Inc BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF
CN103073644B (zh) 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
RU2702108C2 (ru) 2013-07-16 2019-10-04 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
KR102345173B1 (ko) 2014-03-14 2021-12-29 이나뜨 파르마 에스.에이. 증가된 안정성을 가진 인간화 항체
MX2016017288A (es) 2014-07-16 2017-06-27 Genentech Inc Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US20160355589A1 (en) 2014-08-19 2016-12-08 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2016073282A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
HK1243940A1 (zh) 2014-11-06 2018-07-27 Scholar Rock, Inc. 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途
MX2017006485A (es) 2014-11-18 2018-03-23 Janssen Pharmaceutica Nv Anticuerpos anti-cd47, metodos y usos.
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
EP3259597B1 (en) 2015-02-19 2022-04-06 Compugen Ltd. Pvrig polypeptides and methods of treatment
MX374853B (es) 2015-02-19 2025-03-06 Compugen Ltd Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso.
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
WO2017041004A1 (en) 2015-09-02 2017-03-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
MY186016A (en) 2015-09-25 2021-06-14 Genentech Inc Anti-tigit antibodies and methods of use
SG10201912736UA (en) 2015-10-01 2020-02-27 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
WO2018017864A2 (en) 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
SG11201901077RA (en) 2016-08-17 2019-03-28 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
DK3559027T3 (da) 2016-12-23 2022-09-05 Serum Institute Of India Pvt Ltd Fremgangsmåder til forbedring af antistofoproduktivitet i pattedyrecellekultur og minimering af aggregering nedstrøms, formuleringsprocesser og stabile antistofformuleringer opnået deraf
MX2019012381A (es) 2017-05-18 2020-01-23 Hoffmann La Roche Reduccion de reaccion secundaria relacionada con la aplicacion de un anticuerpo terapeutico.
BR112019025035A2 (pt) 2017-06-01 2020-06-30 Compugen Ltd. método para tratar câncer
JP7407118B2 (ja) 2018-02-08 2023-12-28 アムジェン インコーポレイテッド 低ｐＨ医薬抗体製剤
CA3160162A1 (en) 2019-11-04 2021-05-14 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2022222125A1 (zh) 2021-04-23 2022-10-27 京东方科技集团股份有限公司 一种解锁控制方法、装置、电子设备和计算机可读存储介质

Also Published As

Publication number Publication date
ES2929293T3 (es) 2022-11-28
AU2024202336A1 (en) 2024-05-16
US11220542B2 (en) 2022-01-11
ES2786651T3 (es) 2020-10-13
DK3653221T5 (da) 2024-08-26
LT3653221T (lt) 2022-11-10
JP2022106783A (ja) 2022-07-20
RU2732042C2 (ru) 2020-09-10
KR20170137067A (ko) 2017-12-12
EP3295951A1 (en) 2018-03-21
PT3295951T (pt) 2020-07-21
HRP20201066T1 (hr) 2021-02-05
HUE049791T2 (hu) 2020-10-28
US20200148769A1 (en) 2020-05-14
ZA201706323B (en) 2020-05-27
CN107580500B (zh) 2023-05-30
MX374853B (es) 2025-03-06
PT3653221T (pt) 2022-11-08
MX2017010667A (es) 2018-08-15
LT3258951T (lt) 2020-05-11
DK3258951T3 (da) 2020-04-06
CN107580500A (zh) 2018-01-12
RU2020128686A (ru) 2020-10-13
DK3653221T3 (da) 2022-10-24
EP4129320A1 (en) 2023-02-08
IL254039B2 (en) 2023-12-01
SG11201706583PA (en) 2017-09-28
HK1247568A1 (en) 2018-09-28
EP3653221B1 (en) 2022-08-03
ES2806800T3 (es) 2021-02-18
HRP20200572T1 (hr) 2020-08-21
US20240101669A1 (en) 2024-03-28
MX2020009461A (es) 2021-02-17
KR20240090732A (ko) 2024-06-21
CN115350275A (zh) 2022-11-18
AU2020264349A1 (en) 2020-12-03
LT3295951T (lt) 2020-09-25
US12312404B2 (en) 2025-05-27
US20160244521A1 (en) 2016-08-25
IL304117A (en) 2023-09-01
US20170081408A1 (en) 2017-03-23
AU2016219835A1 (en) 2017-09-14
PL3653221T3 (pl) 2022-12-19
PL3295951T3 (pl) 2020-10-05
US20210188974A1 (en) 2021-06-24
EP3258951A1 (en) 2017-12-27
US10351625B2 (en) 2019-07-16
US11623955B2 (en) 2023-04-11
WO2016134333A9 (en) 2017-02-02
JP7115856B2 (ja) 2022-08-09
WO2016134333A1 (en) 2016-08-25
HK1247569A1 (en) 2018-09-28
US10227408B2 (en) 2019-03-12
EP3653221A1 (en) 2020-05-20
AU2016219835B2 (en) 2020-12-03
US9714289B2 (en) 2017-07-25
CA2976926A1 (en) 2016-08-25
JP2018512443A (ja) 2018-05-17
EP3295951B1 (en) 2020-04-22
EP3258951B1 (en) 2020-01-29
IL254039A0 (en) 2017-10-31
RU2017132214A (ru) 2019-03-19
US11795220B2 (en) 2023-10-24
PL3258951T3 (pl) 2020-07-27
CY1123259T1 (el) 2021-12-31
CY1122970T1 (el) 2021-10-29
US20170029504A1 (en) 2017-02-02
HRP20221284T1 (hr) 2022-12-23
DK3295951T3 (da) 2020-07-20
PT3258951T (pt) 2020-08-18
KR102669294B1 (ko) 2024-05-23
HUE061084T2 (hu) 2023-05-28
HUE049032T2 (hu) 2020-08-28
US20250333503A1 (en) 2025-10-30
AU2020264349B2 (en) 2024-05-02
RU2017132214A3 (OSRAM) 2019-08-28
IL254039B1 (en) 2023-08-01
SI3258951T1 (sl) 2020-07-31
US20180244774A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
IL259495A (en) Antibodies and methods for using them
IL257636A (en) Anti-tigit antibodies and methods of use
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
SG11201803567XA (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL251868B (en) Anti-tim3 antibodies and methods of use
IL251970A0 (en) Anti-cd79b antibodies and methods of use
IL259681A (en) New antibodies against claudin and methods of using them
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
HRP20181359T1 (hr) Anti-jagged1 protutijela i postupci uporabe
SG11201702550WA (en) ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use